Late Effects After High-Risk Neuroblastoma – St. Baldrick’s Foundation
St. Baldrick’s Foundation shared on LinkedIn:
“Modern therapies (such as stem cell transplant and immune therapy) have made high-risk neuroblastoma a potentially survivable disease, but little is known about the chronic health issues experienced by survivors.
Understanding the burden of chronic disease in survivors of high-risk neuroblastoma is critical for informing appropriate long-term care of survivors as well as for planning future trials of upfront neuroblastoma therapy.
Through the St. Baldricks’ supported Late Effects After High-Risk Neuroblastoma (LEAHRN) Consortium, researchers will examine the impact of neuroblastoma treatments on survivors’ growth, pubertal development, and long-term health. The LEAHRN Consortium is coordinated by Dr. Tara Henderson at the University of Chicago, and the trial is conducted through the Children’s Oncology Group. Together investigators will assemble the largest known group of high-risk neuroblastoma survivors to evaluate the late effects of modern therapies. This study will also provide a foundation for the development of early detection and prevention strategies for long-term follow-up care.
In honor of National Cancer Survivors Month, help childhood cancer survivors. Your donation will support research like this working to give survivors long and healthy lives.”
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023